“
TL;DR
The central result is that while PICS is a recognized complication affecting a significant portion of SAP patients, its precise mechanisms are not fully understood, and management remains based on expert opinion and integrated measures.
Experimental and Therapeutic Medicine · 4 authors, 1 centre
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
The central result is that while PICS is a recognized complication affecting a significant portion of SAP patients, its precise mechanisms are not fully understood, and management remains based on expert opinion and integrated measures.
It describes PICS as a late-stage complication arising from a dysfunctional immune response (SIRS-CARS-MARS axis) and reports that approximately 43.1% of SAP patients develop it. The review synthesizes concepts from the literature on chronic critical illness and immune paralysis, outlining various proposed therapeutic strategies without reporting original clinical trial data. Key limitations include the lack of a clearly elucidated pathophysiological mechanism for PICS and the reliance on hypothetical and expert-based recommendations. The authors conclude that identifying at-risk patients and conducting rigorous controlled studies are crucial for advancing from experience-based to standardized, goal-oriented precision treatment.